Joke Vereecken

Joke Vereecken is Partner at Theodorus Investment Funds, an early-stage healthcare focused fund. Prior joining Theodurs in 2022, she was principal at Droia Ventures (2014-2022), a >$500m AuM venture capital fund specialized in oncology and genetic disease therapeutics. At Droia she also served as interim CFO at Tusk Therapeutics (sold to Roche in 2018) and as VP Corporate Development of Montis Biosciences and Alesta Therapeutics. She currently also serves on the board of the Brussels South Charleroi Biopark. Joke started her career at the M&A department of EY. She holds a MSc in Commercial Engineering from the University of Leuven.